We did not examine the ruxolitinib pre-infection only condition, as our previous studies showed that ruxolitinib pre-infection treatments are ineffective in PDAC cells due to the rapidly reversible nature of JAK1/JAK2 inhibition by this drug (58). The gene discussed is JAK2; the disease is infection.